Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
April 2015, Vol 6, No 3
April 2015, Vol 6, No 3
Clinical Utility of Genomic Biomarker Tests Questioned
By
Alice Goodman
Personalized Medicine
April 2015, Vol 6, No 3
Orlando, FL—An independent review of the literature suggests that 3 biomarker tests developed for prostate cancer have yet to justify their utility in randomized clinical trials. The 3 tests in question—Prolaris, Decipher, and Oncotype DX for prostate cancer—are being used in practices around the country, cost approximately $3500 per test, and are reimbursable by Medicare depending on the state.
Read Article
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
By
Loretta Fala
Drug Updates
April 2015, Vol 6, No 3
Thyroid cancer, cancer that starts in the thyroid gland, accounts for 3.8% of all cancer cases in the United States.1 There were an estimated 62,980 new cases of thyroid cancer and 1890 deaths resulting from thyroid cancer in 2014.1 Thyroid cancer is most common in people aged 45 to 54 years (median age, 50 years),1 and it occurs 2 to 3 times more often in women than in men.2 The incidence of thyroid cancer has risen steadily in recent years.3 Although this increasing rate can be attributed largely to disease detection at an earlier stage, the incidence of larger tumors has also increased.3
Read Article
What Is a Navigator?
By
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Patient Navigation
,
Policies & Guidelines
April 2015, Vol 6, No 3
You have just been diagnosed with cancer, and one of the first people you meet on your healthcare team is introduced as a navigator. “A what?” you think. “I need doctors, not a GPS!” But over time, you will realize this person is a great guide.
Read Article
The State of Cancer Care in America: Advances and Challenges
By
Alice Goodman
Health Policy
,
Policies & Guidelines
April 2015, Vol 6, No 3
The recently released American Society of Clinical Oncology (ASCO) annual report, “The State of Cancer Care in America, 2015,” is a mixed bag: the report cites multiple advances in the progress against cancer, but also elaborates on the many hurdles in implementing state-of-the-art cancer care for all Americans.
Read Article
Confirming Diagnoses and Identifying Biomarkers Linked to Targeted Treatments with the bioT3 Approach
Interview with the Innovators
April 2015, Vol 6, No 3
An Interview with Ralph V. Boccia, MD, FACP, of Georgetown University
Read Article
Comprehensive Cancer Center Designation Trumps High Volume as Predictor for Outcomes in Ovarian Cancer
By
Charles Bankhead
Gynecologic Oncology Highlights
April 2015, Vol 6, No 3
Chicago, IL—The National Cancer Institute (NCI) designation of a comprehensive cancer center trumps high case volume as a predictor of outcomes in ovarian cancer, according to a single-region analysis.
Read Article
PARP Inhibitor Maintenance Too Pricey for Ovarian Cancer?
By
Charles Bankhead
Gynecologic Oncology Highlights
April 2015, Vol 6, No 3
Chicago, IL—Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy with olaparib (Lynparza) for relapsed, platinum-sensitive ovarian cancer would meet conventional standards of cost-effectiveness only if the drug price decreased by ?66%, according to a modeling study.
Read Article
Bevacizumab Prolongs Survival in Recurrent Platinum-Sensitive Ovarian Cancer
By
Alice Goodman
Gynecologic Oncology Highlights
April 2015, Vol 6, No 3
Chicago, IL—The addition of bevacizumab (Avastin) to standard chemotherapy extended survival in women with platinum-sensitive recurrent ovarian cancer compared with chemotherapy alone in the phase 3 randomized controlled GOG0213 trial. The results were presented at the 2015 Society of Gynecologic Oncology annual meeting.
Read Article
In the Literature - April 2015
In the Literature
April 2015, Vol 6, No 3
Read Article
Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel
By
Wayne Kuznar
NCCN Conference Highlights
April 2015, Vol 6, No 3
Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guideline allows for the upfront use of docetaxel (Taxotere) in some men with castration-resistant prostate cancer (CRPC). This and other systemic therapies represent the most significant changes in the updated guideline for the treatment of patients with metastatic CRPC, said Andrew J. Armstrong, MD, ScM, Co-Leader, Genitourinary Oncology Research Program, Duke Cancer Institute, Durham, NC, at the 2015 NCCN annual conference.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma